Esther Rajavelu
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Esther Rajavelu
Earlier roles on record: CFO at Fulcrum Therapeutics, Inc. (FULC) until April 21, 2023. Fulcrum Therapeutics, Inc. reported in an 8-K filed May 15, 2023 that Esther Rajavelu resigned as chief financial officer, effective April 21, 2023. Fulcrum Therapeutics, Inc. reported in an 8-K filed April 5, 2023 that Esther Rajavelu resigned as chief financial officer and treasurer (and as principal financial officer), effective April 21, 2023. The proxy statement of Fulcrum Therapeutics, Inc. reports total compensation of $3,349,680 for Esther Rajavelu in fiscal 2022, including a base salary of $435,000. Esther Rajavelu has spoken on 4 earnings calls across 1 company, most recently for Fulcrum Therapeutics, Inc. on November 8, 2022.
“Esther Rajavelu resigned as chief financial officer, effective April 21, 2023.”
“On March 31, 2023, Esther Rajavelu notified Fulcrum Therapeutics, Inc., or Fulcrum, of her intent to resign as chief financial officer and treasurer (and as principal financial officer), effective April 21, 2023, to pursue another opportunity.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
2022-01-03–2023-04-21
-
Start not stated–2023-04-21
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Fulcrum Therapeutics, Inc. (FULC) | Former Chief Financial Officer | $435,000 | $3,349,680 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.